Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial - Frias, JP; Nauck, MA; Van, J (Lancet, 2018)
et al.